Package Leaflet: Information for the Patient
Neoclarityn 5 mg Film-Coated Tablets
desloratadine
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
What is Neoclarityn
Neoclarityn contains desloratadine, which is an antihistamine.
How Neoclarityn works
Neoclarityn is an anti-allergic medicine that does not cause drowsiness. It helps to control the allergic reaction and its symptoms.
When to use Neoclarityn
Neoclarityn relieves the symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, such as hay fever or allergy to dust mites) in adults and adolescents aged 12 years and older. These symptoms include sneezing, runny or itchy nose, itchy palate, and itchy, red, or watery eyes.
Neoclarityn is also used to relieve the symptoms associated with urticaria (a skin disease caused by an allergy). These symptoms include itching and skin rash.
The relief of these symptoms lasts a full day and helps you to continue your daily activities and normal sleep periods.
Do not take Neoclarityn
Warnings and precautions
Consult your doctor, pharmacist, or nurse before taking Neoclarityn:
Children and adolescents
Do not give this medicine to children under 12 years of age.
Other medicines and Neoclarityn
There are no known interactions of Neoclarityn with other medicines. Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Taking Neoclarityn with food, drinks, and alcohol
Neoclarityn can be taken with or without food. Be careful when taking Neoclarityn with alcohol.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. It is not recommended to take Neoclarityn if you are pregnant or breastfeeding. There is no data available on male and female fertility.
Driving and using machines
At the recommended dose, it is not expected that this medicine will affect your ability to drive or use machines. Although most people do not experience drowsiness, it is recommended not to engage in activities that require a state of alertness, such as driving a car or using machines, until you have determined your own response to the medicine.
Neoclarityn tablets contain lactose
If your doctor has told you that you have an intolerance to some sugars, contact them before taking this medicine.
Follow exactly the instructions of your doctor or pharmacist. If you are not sure, ask your doctor or pharmacist again.
Use in adults and adolescents aged 12 years and older
The recommended dose is one tablet once daily with water, with or without food.
This medicine is for oral use.
Swallow the tablet whole.
Regarding the duration of treatment, your doctor will determine the type of allergic rhinitis you have and how long you should take Neoclarityn.
If your allergic rhinitis is intermittent (symptoms present for less than 4 days a week or for less than 4 weeks), your doctor will recommend a treatment schedule based on the evaluation of your disease history.
If your allergic rhinitis is persistent (symptoms present for 4 or more days a week and for more than 4 weeks), your doctor may recommend long-term treatment.
For urticaria, the duration of treatment may vary from one patient to another, and you should follow your doctor's instructions.
If you take more Neoclarityn than you should
Take Neoclarityn only as your doctor has told you. It is not expected that an accidental overdose will cause serious problems. However, if you take more Neoclarityn than you should, tell your doctor, pharmacist, or nurse immediately.
If you forget to take Neoclarityn
If you forget to take your dose at the scheduled time, take it as soon as possible and then continue with your normal dosing schedule. Do not take a double dose to make up for forgotten doses.
If you stop taking Neoclarityn
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
During the marketing of Neoclarityn, very rare cases of severe allergic reactions (difficulty breathing, wheezing, itching, rash, and swelling) have been reported. If you experience any of these serious side effects, stop taking this medicine and seek medical attention immediately.
In clinical trials in adults, the side effects were approximately the same as with a placebo. However, fatigue, dry mouth, and headache were reported more frequently than with a placebo. In adolescents, headache was the most commonly reported adverse reaction.
In clinical trials with Neoclarityn, the following side effects were reported:
Frequent: may affect up to 1 in 10 people
Very rare: may affect up to 1 in 10,000 people
Frequency not known: cannot be estimated from the available data
Children
Frequency not known: cannot be estimated from the available data
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date is the last day of the month stated.
Do not store above 30°C. Store in the original package.
Do not use this medicine if you notice any change in the appearance of the tablets.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Neoclarityn
Appearance and packaging of the product
Neoclarityn 5 mg film-coated tablets are light blue, round, and engraved with the letters "S" and "P" on one side and smooth on the other.
Neoclarityn 5 mg film-coated tablets are available in blisters in packs of 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 30, 50, or 100 tablets.
Not all pack sizes may be marketed.
Marketing authorisation holder and manufacturer
Marketing authorisation holder:
N.V. Organon
Kloosterstraat 6
5349 AB Oss
Netherlands
Manufacturer:
SP Labo N.V., Industriepark 30, B-2220 Heist-op-den-Berg, Belgium.
For further information on this medicine, contact the local representative of the marketing authorisation holder:
Belgium Organon Belgium Tel: 0080066550123 (+32 2 2418100) dpoc.benelux@organon.com | Lithuania Organon Pharma B.V. Lithuania branch Tel: +370 52041693 dpoc.lithuania@organon.com |
Bulgaria Organon Bulgaria EOOD Tel: +359 2 806 3030 dpoc.bulgaria@organon.com | Luxembourg Organon Belgium Tel: 0080066550123 (+32 2 2418100) dpoc.benelux@organon.com |
Czech Republic Organon Czech Republic s.r.o. Tel: +420 233 010 300 dpoc.czech@organon.com | Hungary Organon Hungary Kft. Tel: +36 1 766 1963 dpoc.hungary@organon.com |
Denmark Organon Denmark ApS Tel: +45 4484 6800 info.denmark@organon.com | Malta Organon Pharma B.V., Cyprus branch Tel: +356 2277 8116 dpoc.cyprus@organon.com |
Germany Organon Healthcare GmbH Tel: 0800 3384 726 (+49 (0) 89 2040022 10) dpoc.germany@organon.com | Netherlands N.V. Organon Tel: 00800 66550123 (+32 2 2418100) dpoc.benelux@organon.com |
Estonia Organon Pharma B.V. Estonian RO Tel: +372 66 61 300 dpoc.estonia@organon.com | Norway Organon Norway AS Tel: +47 24 14 56 60 info.norway@organon.com |
Greece N.V. Organon Tel: +30-216 6008607 | Austria Organon Austria GmbH Tel: +43 (0) 1 263 28 65 medizin-austria@organon.com |
Spain Organon Salud, S.L. Tel: +34 91 591 12 79 organon_info@organon.com | Poland Organon Polska Sp. z o.o. Tel: +48 22 105 50 01 organonpolska@organon.com |
France Organon France Tel: +33 (0) 1 57 77 32 00 | Portugal Organon Portugal, Sociedade Unipessoal Lda. Tel: +351 218705500 geral_pt@organon.com |
Croatia Organon Pharma d.o.o. Tel: +385 1 638 4530 dpoc.croatia@organon.com | Romania Organon Biosciences S.R.L. Tel: +40 21 527 29 90 info.romania@organon.com |
Ireland Organon Pharma (Ireland) Limited Tel: +353 15828260 medinfo.ROI@organon.com | Slovenia Organon Pharma B.V., Oss, branch Ljubljana Tel: +386 1 300 10 80 info.slovenia@organon.com |
Iceland Vistor hf. Tel: +354 535 7000 | Slovakia Organon Slovakia s. r. o. Tel: +421 2 44 88 98 88 dpoc.slovakia@organon.com |
Italy Organon Italia S.r.l. Tel: +39 06 3336407 dpoc.italy@organon.com | Finland Organon Finland Oy Tel: +358 (0) 29 170 3520 dpoc.finland@organon.com |
Cyprus Organon Pharma B.V., Cyprus branch Tel: +357 22866730 dpoc.cyprus@organon.com | Sweden Organon Sweden AB Tel: +46 8 502 597 00 dpoc.sweden@organon.com |
Latvia Organon Pharma B.V. representative office Tel: +371 66968876 dpoc.latvia@organon.com | United Kingdom (Northern Ireland) Organon Pharma (Ireland) Limited Tel: +353 15828260 medinfo.ROI@organon.com |
Date of last revision of this leaflet: MM/AAAA.
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.